National mass drug administration costs for lymphatic filariasis elimination

Show simple item record

dc.contributor.author Goldman, A.S.
dc.contributor.author Guisinger, V.H.
dc.contributor.author Aikins, M.
dc.contributor.author Amarillo, M.L.A.
dc.contributor.author Belizario, V.Y.
dc.contributor.author Garshong, B.
dc.contributor.author Gyapong, J.
dc.contributor.author Kabali, C.
dc.contributor.author Kamal, H.A.
dc.contributor.author Kanjilal, S.
dc.contributor.author Kyelem, D.
dc.contributor.author Lizardo, J.
dc.contributor.author Malecela, M.
dc.contributor.author Mubyazi, G.
dc.contributor.author Nitiema, P.A.
dc.contributor.author Ramzy, R.M.
dc.contributor.author Streit, T.G.
dc.contributor.author Wallace, A.
dc.contributor.author Brady, M.A.
dc.contributor.author Rheingans, R.
dc.contributor.author Ottesen, E.A.
dc.contributor.author Haddix, A.C.
dc.date.accessioned 2013-06-20T11:19:01Z
dc.date.accessioned 2017-10-16T12:28:50Z
dc.date.available 2013-06-20T11:19:01Z
dc.date.available 2017-10-16T12:28:50Z
dc.date.issued 2007-10-31
dc.identifier.citation Goldman, A. S., Guisinger, V. H., Aikins, M., Amarillo, M. L. E., Belizario, V. Y., Garshong, B., . . .Haddix, A. C. (2007). National mass drug administration costs for lymphatic filariasis elimination.PLoS Neglected Tropical Diseases, 1(1) en_US
dc.identifier.uri http://197.255.68.203/handle/123456789/3726
dc.description.abstract BACKGROUND: Because lymphatic filariasis (LF) elimination efforts are hampered by a dearth of economic information about the cost of mass drug administration (MDA) programs (using either albendazole with diethylcarbamazine [DEC] or albendazole with ivermectin), a multicenter study was undertaken to determine the costs of MDA programs to interrupt transmission of infection with LF. Such results are particularly important because LF programs have the necessary diagnostic and treatment tools to eliminate the disease as a public health problem globally, and already by 2006, the Global Programme to Eliminate LF had initiated treatment programs covering over 400 million of the 1.3 billion people at risk. METHODOLOGY/PRINCIPAL FINDINGS: To obtain annual costs to carry out the MDA strategy, researchers from seven countries developed and followed a common cost analysis protocol designed to estimate 1) the total annual cost of the LF program, 2) the average cost per person treated, and 3) the relative contributions of the endemic countries and the external partners. Costs per person treated ranged from $0.06 to $2.23. Principal reasons for the variation were 1) the age (newness) of the MDA program, 2) the use of volunteers, and 3) the size of the population treated. Substantial contributions by governments were documented - generally 60%-90% of program operation costs, excluding costs of donated medications. CONCLUSIONS/SIGNIFICANCE: MDA for LF elimination is comparatively inexpensive in relation to most other public health programs. Governments and communities make the predominant financial contributions to actual MDA implementation, not counting the cost of the drugs themselves. The results highlight the impact of the use of volunteers on program costs and provide specific cost data for 7 different countries that can be used as a basis both for modifying current programs and for developing new ones. en_US
dc.title National mass drug administration costs for lymphatic filariasis elimination en_US
dc.type Article en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search UGSpace


Browse

My Account